US equities |
MU $969.85 ▲+4.42% META $614.61 ▼-0.90% TSLA $401.48 ▼-1.47% SPCX $144.56 ▼-2.71% SNDK $1,379.09 ▲+5.69% NVDA $217.31 ▼-0.29% SKHY $163.47 ▲+12.46% STX $677.38 ▲+1.43%
FinancialContent

ClearPoint Neuro Inc. - Common Stock (NQ:CLPT)

10.32 +0.63 (+6.55%)
Delayed Quote Updated: 11:57 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ClearPoint Neuro Inc. - Common Stock

< Previous 1 2 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
From ClearPoint Neuro, Inc.
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
ClearPoint Neuro Reports Second Quarter 2026 Results
From ClearPoint Neuro, Inc.
Via ACCESS Newswire
News headline image
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
From ClearPoint Neuro, Inc.
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
From ClearPoint Neuro, Inc.
Via ACCESS Newswire
News headline image
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports First Quarter 2026 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Via ACCESS Newswire
News headline image
ClearPoint Neuro Completes Acquisition of IRRAS
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports Third Quarter 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Agreement to Acquire IRRAS
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports Second Quarter 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025
Via ACCESS Newswire
< Previous 1 2 Next >